Lung Cancer
Volume 45, Supplement , Pages S35-S36, August 2004

Pathology of malignant mesothelioma

Laboratory of Pathology, University Hospital of Antwerp, Wilrijkstraat 10, Edegem B-2650, Belgium

Abstract 

The diagnosis of malignant mesothelioma relies firstly on the identification of the mesothelial nature of the neoplastic cell and secondly on the demonstration of the invasive properties of the proliferation. The latter aspect cannot be achieved by studying cellular material yet, in the right clinical setting, it is often possible to make a presumptive diagnosis of malignant mesothelioma based on exudates. Differentiation between mesothelial hyperplasia and metastatic adenocarcinoma by cytological examination alone is unreliable, so further evidence can be gathered from techniques such as histopathology, histochemistry and electron microscopy. Immunohistochemistry aims to confirm the mesothelial nature of the neoplastic cells while ruling out metastatic lesions. At present there is no single reliable marker for neoplastic mesothelioma, although evidence has been presented on a large variety of gene products. In an attempt to differentiate between hyperplastic mesothelium and malignant mesothelioma, Dhaene has been able to show that over 90% of malignant mesotheliomas show telomerase activity and express telomerase subunits.

Keywords:  Malignant mesothelioma, Neoplastic mesothelium, Calretinin, Telomerase activity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(04)00169-2

doi:10.1016/j.lungcan.2004.04.006

Lung Cancer
Volume 45, Supplement , Pages S35-S36, August 2004